Demographics and Oncological Parameters
| Minimally Invasive Surgery (n=43) | Open Surgery (n=51) | P-value | |
|---|---|---|---|
| − Age (mean ± SD) − Parity (mean ± SD) − Caesarean section (mean ± SD) | − 55.7±7.31 − 1.62±1.31 − 0.3±0.62 | − 55.37±8.1 − 2.0±1.76 − 0.31±0.79 | − 0.83 − 0.29 − 0.96 |
| Stage | − Stage 1A: 63% (27/43) − Stage IB: 30% (13/43) − Stage II: 7% (3/43) | − Stage 1A: 56.9% (29/51) − Stage 1B: 15.7% (8/51) − Stage II: 27.5% (14/51) | 0.02 |
| Grade | − Grade 1: 52.4% (22/42) − Grade 2: 26.2% (11/42) − Grade 3: 21.4% (9/42) − Missing: 1 | − Grade 1: 43.8% (21/48) − Grade 2: 35.4% (17/48) − Grade 3: 20.8% (10/48) − Missing: 3 | 0.18 |
| Histology | − Endometrioid: 95.2% (40/42) − Serous adenocarcinoma: 2.4% (1/42) − Undifferentiated adenocarcinoma: 2.4% (1/42) − Missing: 1 | − Endometrioid: 92.2% (47/51) − Serous adenocarcinoma: 2% (1/51) − Undifferentiated adenocarcinoma: 2% (1/51) − Clear cell carcinoma: 3.9% (2/51) | 0.48 |
| Lymph node enlarged on MRI | − Pelvic lymph node enlarged: 17.1% (7/41) − Para-aortic lymph node enlarged: 0% (0/40) | − Pelvic lymph node enlarged: 36% (18/50) − Para-aortic lymph node enlarged: 2.3% (1/44) | 0.08 0.28 |
| Radical hysterectomy | 4.7% (2/43) | 11.8% (6/51) | 0.39 |
| LVSI present | 26.5% (9/34) | 28.6% (10/35) | 1 |
| − Adjuvant vault radiotherapy − Adjuvant external radiotherapy − Chemotherapy | − 33.3% (14/42) − 9.5% (4/42) − 7.1% (3/42) | − 37.3% (19/51) − 25.5% (13/51) − 9.8% (5/51) | − 0.34 − 0.09 − 0.93 |
| − Recurrence − 5 year disease free survival − 5 year overall survival | − 14% (6/43) − 80% (31/39) − 87% (34/39) | − 5.9% (3/51) − 92% (46/50) − 94% (47/50) | − 0.33 − 0.16 − 0.46 |